- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07716969
TOPUS - Testing an Implemented Intervention to Reduce Duration of Untreated Psychosis (TOPUS)
Duration of Untreated Psychosis Revisited - Testing the Effect of Early Detection Services on the Duration of Untreated Psychosis. the TOPUS Study
This study examines whether an early-detection program for psychosis can shorten the time patients remain untreated after the first appearance of psychotic symptoms, and whether such a reduction improves later functioning for people with first-episode schizophrenia.
Psychosis involves symptoms such as hallucinations and delusions. When these symptoms are recognized and treatment begins, most patients improve. However, many individuals live with psychotic symptoms for months-or even longer-before receiving care. This period is known as the duration of untreated psychosis (DUP). A long DUP has repeatedly been linked to poorer long-term outcomes, but it is still unclear whether DUP itself causes worse outcomes or simply reflects different illness courses.
In Denmark, Region Zealand has implemented a large-scale early-detection effort. This includes public awareness campaigns and a specialized team that identifies people with emerging psychosis and helps them start treatment quickly. The Capital Region of Denmark provides usual care without these additional initiatives. This situation makes it possible to compare two regional systems that differ in their approach to early detection but provide the same specialized treatment once patients enter care.
The study follows a quasi-experimental design, recruiting adults (18+) who receive a first diagnosis of a schizophrenia-spectrum disorder within the OPUS early-intervention programs in the two regions. No interventions are assigned by the research team; participants receive standard clinical care. Researchers conduct interviews to establish how long psychotic symptoms were present before treatment began and to assess functioning and symptoms over a two-year follow-up period. Functioning, symptoms, cognition, and treatment factors will be examined at baseline and at follow-ups.
The study addresses three questions:
Whether early-detection efforts in Region Zealand reduce the duration of untreated psychosis compared with usual detection.
Whether a shorter duration of untreated psychosis leads to better functional and clinical outcomes fifteen months after treatment begins.
How DUP can best be defined and measured so that it reliably predicts later outcomes.
Results may provide evidence for whether early-detection services improve timely access to care and whether reducing the duration of untreated psychosis contributes to better long-term functioning. The study may also help establish clearer international standards for how DUP should be measured in both research and clinical practice.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
This study investigates whether a large-scale early-detection program for psychosis implemented in one Danish health region reduces the duration of untreated psychosis (DUP) and whether a shorter DUP leads to improved clinical and functional outcomes. The project takes advantage of an existing difference between two regions in Denmark: Region Zealand has, for more than a decade, operated campaign-supported early-detection teams, whereas the Capital Region provides standard detection pathways without additional outreach. Both regions deliver identical specialized treatment once patients enter the OPUS early-intervention services. This natural difference creates a unique opportunity to evaluate the real-world impact of early-detection efforts.
Scientific Rationale
DUP refers to the time between the onset of psychotic symptoms and the start of appropriate treatment. Prolonged DUP is consistently associated with worse outcomes, including more severe symptoms and poorer functioning. However, most existing evidence comes from observational studies that cannot rule out the possibility that long DUP is simply a marker of more severe or insidiously developing illness rather than a direct causal factor. The field therefore lacks strong evidence on whether active reduction of DUP improves outcomes.
Some early-detection initiatives-most prominently the TIPS study-have demonstrated that campaigns combined with rapid-access teams can significantly reduce DUP and may influence long-term functioning. However, not all attempts to reduce DUP have succeeded, and no consensus exists on the most effective strategy. It also remains uncertain how DUP should best be defined and operationalized, as several different definitions are used in the literature.
The present study is designed to help address these gaps. It examines whether an established early-detection strategy in Region Zealand has in fact shortened DUP compared with usual detection, whether any reduction has meaningful effects on two-year outcome trajectories, and which definitions of DUP provide the most reliable predictive value.
Study Design
The project uses a quasi-experimental design with two non-overlapping recruitment areas. Participants are adults with a first diagnosis of a schizophrenia-spectrum disorder who have entered OPUS treatment in either Region Zealand (early-detection region) or the Capital Region (comparison region). No experimental intervention is delivered by the research team. All participants receive routine clinical care as determined by their local OPUS center. The research activities consist of structured assessments conducted at baseline and during follow-up.
Because patients are recruited within established treatment programs and no treatment allocation is made, the study does not involve randomization or modification of clinical care. The design instead tests whether an existing system-level initiative-public awareness campaigns, stakeholder outreach, and a specialized early-detection team-has produced measurable differences in DUP and outcomes.
Study Objectives
The project is organized around three central objectives:
Effectiveness of Early Detection (WQ1):
Determine whether the early-detection initiatives in Region Zealand reduce DUP in first-episode schizophrenia compared with the Capital Region.
Impact of DUP on Outcomes (WQ2):
Evaluate whether variation in DUP predicts fifteen months functional and psychopathological outcomes within the cohort.
Operationalization of DUP (WQ3):
Compare different definitions and measurement approaches to identify how DUP is most reliably assessed and how different operationalizations affect its predictive power.
Assessments and Data Collection
At baseline, participants complete structured clinical interviews and psychometric assessments focusing on psychopathology, functioning, premorbid adjustment, cognition, and pathways to care. The measurement of DUP is central: the study uses the Nottingham Onset Schedule (NOS) as the primary tool, and definitions distinguishing between patient-level delay ("DUP Demand"), system-level delay ("DUP Supply"), and total DUP.
To examine trajectories after treatment begins, participants are contacted at 3 and 9 months for focused follow-up assessments, and they undergo a comprehensive fifteen months evaluation of functioning, symptoms, cognition, suicidality, and treatment factors. Register-based data on education, employment, hospitalization, and family formation supplement missing or incomplete follow-up information.
Analytical Approach
Because DUP is typically skewed, analyses will apply appropriate transformations or non-parametric approaches. Comparisons between regions will adjust for relevant confounders. Functional and symptom outcomes will be evaluated using regression models, and trajectories across the fifteen month period will be explored using latent class growth analysis to identify distinct functional subgroups. Multiple imputation will be used for handling missing follow-up data.
Expected Contributions
This study is among the few to evaluate early-detection efforts under real-world conditions in a public mental-health system. By comparing two regions with stable, well-defined differences in detection practices but identical treatment programs, the design provides an opportunity to examine both the system-level impact on DUP and the clinical implications of altered detection timing.
The results are expected to address three major uncertainties in the field:
whether early-detection campaigns and outreach teams meaningfully reduce the time patients remain untreated,
whether a reduced DUP improves functional and clinical outcomes, and
how DUP should be operationalized to provide the clearest and most clinically relevant information.
Establishing the effectiveness of an already-implemented early-detection model has the potential to inform service planning in Denmark and internationally. In addition, clarifying the causal role of DUP could support future health-care strategies aimed at minimizing untreated psychosis, and the project's methodological work may contribute to consensus definitions for DUP in both clinical and research settings.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Nikolai Albert, MD, PhD
- Telefonnummer: +45 29925014
- E-Mail: nikolai.albert@regionh.dk
Studieren Sie die Kontaktsicherung
- Name: Stephen F Austen, PhD
- Telefonnummer: +45 23259577
- E-Mail: stfa@regionsjaelland.dk
Studienorte
-
-
Denmark
-
Copenhagen, Denmark, Dänemark, 2900
- Rekrutierung
- Mental Health Centre Copenhagen
-
Kontakt:
- Nikolai Albert, MD, PhD
- Telefonnummer: +45 29925014
- E-Mail: nikolai.albert@regionh.dk
-
Hauptermittler:
- Nikolai Albert, MD, PhD
-
Kontakt:
- Stephen F Austen, PhD
- Telefonnummer: +45 23259577
- E-Mail: stfa@regionsjaelland.dk
-
Roskilde, Denmark, Dänemark, 4000
- Rekrutierung
- Region Zealand Psychiatry East
-
Kontakt:
- Stephen F Austin, PhD
- Telefonnummer: +45 23259577
- E-Mail: stfa@regionsjaelland.dk
-
Kontakt:
- Marie L Olsen, MD
- Telefonnummer: +45 22915210
- E-Mail: malag@regionsjaelland.dk
-
Hauptermittler:
- Stephen f Austin, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
18 or older In treatement in an OPUS treatment center in The Capital Region or Region Zealand.
Started OPUS treatment within the last 9 months Suspected to have a psychotic disorder within the ICD 10 Schizophrenia spectrum (DF2X, excluding schizotypal disorder and schizophrenia simplex) Able to communicate adequately regarding symptoms and functioning in Danish or English.
-
Exclusion Criteria:
- IQ bellow 70 I primary diagnoses of drug or alcohol dependency
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Cohort 1: Region Zealand Early-Detection Cohort
Participants identified through in a region with a early-detection program, which could identify participants prior to OPUS treatment
|
Participants receive standard clinical care independent of the study.
No intervention is assigned by investigators.
|
|
Cohort 2: Capital Region Usual-Detection Cohort
|
Participants receive standard clinical care independent of the study.
No intervention is assigned by investigators.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Duration of Untreated Psychosis measured with the NOS
Zeitfenster: From start inclusion, marts 2024, to end inclusion marts 2027
|
From start inclusion, marts 2024, to end inclusion marts 2027
|
|
|
PSP
Zeitfenster: From beginning of 15 months follow-up, May 2025, until end of follow-up, September 2028
|
Personal and Social Performance Scale
|
From beginning of 15 months follow-up, May 2025, until end of follow-up, September 2028
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Nikolai Albert, Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- H-23040813
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur No intervention (Observational Study)
-
Royal Marsden NHS Foundation TrustFondazione IRCCS Istituto Nazionale dei Tumori, Milano; Cancer Research UK; University... und andere MitarbeiterRekrutierungSarkom | Weichgewebe-Sarkom Erwachsener | Liposarkom | Angiosarkom | Weichteilsarkom des Gliedes | Retroperitoneales Sarkom | Liposarkom, entdifferenziert | Leiomyosarkom (LMS) | Weichteilsarkom des Rumpfes und der Extremitäten | Weichteilsarkom (STS) | Sarkom, Leiomyo-, Erwachsene | Sarkom, Synovial, ErwachseneVereinigtes Königreich
-
RTI InternationalNo Means No WorldwideAbgeschlossenSexuelle Gewalt | Geschlechtsspezifische GewaltSüdafrika
-
University of Illinois at ChicagoUniversity of Chicago; The Broad FoundationAbgeschlossenColitis ulcerosaVereinigte Staaten
-
King's College LondonMedical University of Graz; Radboud University Medical Center; Novo Nordisk A/S; Juvenile Diabetes Research Foundation und andere MitarbeiterAbgeschlossenDiabetes mellitus, Typ 2 | Hypoglykämie | Diabetes mellitus, Typ 1 | Hypoglykämie-WahrnehmungsstörungVereinigtes Königreich
-
Seattle Institute for Biomedical and Clinical ResearchNational Institute on Alcohol Abuse and Alcoholism (NIAAA); University of Washington und andere MitarbeiterAbgeschlossenAlkoholismus | Belastungsstörungen, posttraumatischVereinigte Staaten